The efficacy of subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy
Authors:
- 19 August 2020
- journal article
- research article
- Published by Springer Nature in Lasers in Medical Science
- Vol. 36 (5) , 981-988
Abstract
Central serous chorioretinopathy (CSC) is a disease characterized by a well-defined serous detachment of the neurosensory retina. Therapeutic options in chronic cases are limited, and side effects can result in a limited response. The aim of this article is to assess the efficacy of subthreshold micropulse laser therapy in patients with chronic central serous chorioretinopathy. The study included 20 eyes of 19 patients who had a history of chronic or chronic recurrent CSC and who underwent subthreshold micropulse laser therapy between January 2015 and June 2018. Twenty eyes of 19 patients with a mean age of 48.9 ± 9.40 years were included. The mean visual acuity was 0.24 ± 0.28 logMAR before laser, 0.19 ± 0.25 logMAR 3 months after laser, and 0.18 ± 0.27 logMAR after 6 months. A statistically significant difference was determined in terms of visual acuity before and after treatment (p = 0.0001). The mean central retinal thickness was 308.10 ± 95.25 μm before laser, 233.65 ± 81.17 μm 3 months after laser, and 203.88 ± 72.79 μm at 6 months. A statistically significant relationship was present between visual acuity and the duration of disease (p = 0.001), between visual acuity and the outer nuclear layer thickness (p = 0.005), and between the outer nuclear layer thickness and the duration of disease in chronic cases (p = 0.008). There was no evidence of retinal pigment epithelium or retinal damage on optical coherence tomography or fundus autofluorescence secondary to subthreshold micropulse laser therapy. Visual acuity appears to be more associated with the duration of disease and with changes in the outer nuclear layer thickness in chronic CSC. Subthreshold micropulse laser therapy seems to be effective at treating chronic CSC, while it increases success during early period of the disease before the development of permanent retinal damage.Keywords
This publication has 30 references indexed in Scilit:
- Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathyEye, 2011
- FLUORESCEIN ANGIOGRAPHY-GUIDED PHOTODYNAMIC THERAPY WITH HALF-DOSE VERTEPORFIN FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHYRetina, 2010
- CLINICAL FACTORS RELATED TO VISUAL OUTCOME IN CENTRAL SEROUS CHORIORETINOPATHYRetina, 2010
- Intravitreal Bevacizumab in Treatment of Idiopathic Persistent Central Serous Chorioretinopathy: A Prospective, Controlled Clinical StudyCurrent Eye Research, 2010
- Outer Nuclear Layer Thickness at the Fovea Determines Visual Outcomes in Resolved Central Serous ChorioretinopathyAmerican Journal of Ophthalmology, 2009
- Subthreshold Diode Micropulse Photocoagulation for the Treatment of Chronic Central Serous Chorioretinopathy with Juxtafoveal LeakageOphthalmology, 2008
- Central serous chorioretinopathyActa Ophthalmologica, 2008
- Chronic central serous chorioretinopathy: photodynamic therapyAmerican Journal of Ophthalmology, 2004
- Risk factors for central serous chorioretinopathyOphthalmology, 2004
- Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy.British Journal of Ophthalmology, 1988